er-086526 and Sarcoma--Ewing

Ewing's sarcoma is a recalcitrant tumor greatly in need of more effective therapy. The aim of this study was to determine the efficacy of eribulin on a doxorubicin (DOX)-resistant Ewing's sarcoma patient derived orthotopic xenograft (PDOX) model. The Ewing's sarcoma PDOX model was previously established in the right chest wall of nude mice from tumor resected form the patient's right chest wall. In the previous study, the Ewing's sarcoma PDOX was resistant to doxorubicin (DOX) and sensitive to palbociclib and linsitinib. In the present study, the PDOX models were randomized into three groups when the tumor volume reached 60 mm

Topics: Administration, Intravenous; Animals; Body Weight; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Furans; Humans; Injections, Intraperitoneal; Ketones; Mice; Mice, Nude; Random Allocation; Sarcoma, Ewing; Treatment Outcome; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays